S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
NASDAQ:FBIOP

Fortress Biotech (FBIOP) Stock Price, News & Analysis

$15.75
+0.20 (+1.29%)
(As of 11:59 AM ET)
Today's Range
$15.75
$15.99
50-Day Range
$13.80
$17.43
52-Week Range
$6.40
$18.91
Volume
277 shs
Average Volume
12,772 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
14.86%
Price Target
N/A
FBIOP stock logo

About Fortress Biotech Stock (NASDAQ:FBIOP)

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

FBIOP Stock Price History

FBIOP Stock News Headlines

Urgent alert: open this for a huge profit potential
This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.
Fortress Biotech Stock (NASDAQ:FBIO) Insider Trades
Insider Stock Buying Reaches US$3.06m On Fortress Biotech
Urgent alert: open this for a huge profit potential
This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.
Fortress Biotech Inc (CNB1.SG)
Nasdaq Down Over 100 Points; Fortress Biotech Shares Plummet
Fortress Biotech Shares Drop After Offering Gets Priced
Fortress Biotech Inc FBIO
See More Headlines
Receive FBIOP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/31 Dividend
3/14/2024
Dividend Payable
3/31/2024
Ex-Dividend for 4/30 Dividend
4/12/2024
Today
4/19/2024
Dividend Payable
4/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:FBIOP
Fax
N/A
Employees
187
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$84.51 million

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Lindsay Allan Rosenwald (Age 69)
    Executive Chairman, President & CEO
    Comp: $942.78k
  • Mr. Michael S. Weiss Esq. (Age 58)
    Vice Chairman & Executive Vice Chairman of Strategic Development
    Comp: $167.92k
  • Mr. David Jin (Age 33)
    CFO & Head of Corporate Development
    Comp: $976.96k
  • Dr. George C. Avgerinos (Age 70)
    Senior Vice President of Biologics Operations
    Comp: $386.49k
  • Mr. Samuel Berry
    General Counsel & Corporate Secretary

FBIOP Stock Analysis - Frequently Asked Questions

How have FBIOP shares performed in 2024?

Fortress Biotech's stock was trading at $11.87 at the beginning of the year. Since then, FBIOP shares have increased by 32.7% and is now trading at $15.75.
View the best growth stocks for 2024 here
.

Are investors shorting Fortress Biotech?

Fortress Biotech saw a drop in short interest in March. As of March 31st, there was short interest totaling 4,800 shares, a drop of 14.3% from the March 15th total of 5,600 shares. Based on an average trading volume of 11,900 shares, the days-to-cover ratio is currently 0.4 days.
View Fortress Biotech's Short Interest
.

How often does Fortress Biotech pay dividends? What is the dividend yield for Fortress Biotech?

Fortress Biotech declared a monthly dividend on Friday, April 12th. Investors of record on Monday, April 15th will be paid a dividend of $0.1953 per share on Tuesday, April 30th. This represents a $2.34 annualized dividend and a dividend yield of 14.88%. The ex-dividend date is Friday, April 12th.
Read our dividend analysis for FBIOP
.

Is Fortress Biotech a good dividend stock?

Fortress Biotech (NASDAQ:FBIOP) pays an annual dividend of $2.34 per share and currently has a dividend yield of 12.11%. FBIOP has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for FBIOP.

How do I buy shares of Fortress Biotech?

Shares of FBIOP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FBIOP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners